Article Details
Retrieved on: 2022-06-05 19:58:43
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The drug, which AstraZeneca licensed from Merck in 2013, is designed to target the WEE1 kinase and cause DNA damage. It has shown activity in ovarian ...
Article found on: www.precisiononcologynews.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here